Extracorporeal CO2 Removal Devices Market is expected to reach US$182.88 Million by 2031

Extracorporeal CO2 Devices Segment to Lead Extracorporeal CO2 Removal Devices Market Based on Product During 2025–2031

According to our new research study on “Extracorporeal CO2 Removal Devices Market Forecast to 2031 – Global Analysis – by Product, Application, and End User,” the extracorporeal CO2 removal devices market size is expected to grow from US$ 112.50 million in 2024 to US$ 182.88 million by 2031; the market is anticipated to register a CAGR of 7.3% during 2025–2031. Major factors driving the growth of the extracorporeal CO2 removal devices market include the rising prevalence of respiratory diseases, growing awareness of minimally invasive procedures, and an increasing geriatric population.

Extracorporeal CO? removal devices represent the next level of respiratory assistance, used to remove carbon dioxide from the patient's bloodstream. It is commonly used in cases of acute or chronic respiratory failure. The system removes blood from the body, and then it flows through a gas exchange membrane where carbon dioxide is removed. ECCO?R devices can be used as a method of lung-protective ventilation, which reduces the risk of ventilator-induced lung injury, especially in conditions such as COPD and ARDS. The increased prevalence of respiratory disorders escalates the demand for these devices, the progression of technology, and the rise in the number of patients admitted to ICUs. Although these are the equipment of intensive care units, their use is expanding to non-ICU locations.

Extracorporeal CO2 Removal Devices Market, by Region, 2024 (%)

Source: The Insight Partners Analysis

Extracorporeal CO2 Removal Devices Market Analysis Based on Segmental Evaluation:

Extracorporeal CO2 devices and consumables are products within the market segment of extracorporeal CO2 removal devices. Extracorporeal CO2 devices accounted for the largest market share of extracorporeal CO2 removal devices in 2024. The extracorporeal CO2 removal (ECCO?R) devices market is a segment of advanced respiratory support that is experiencing rapid growth. The main reason for such growth is the prevalence of severe respiratory conditions worldwide, with ARDS and COPD being notable examples. The radical growth has come from the clinical setting, where ECCO?R devices have proven their worth, particularly when they permit ultraprotective lung ventilation strategies. Thus, clinicians are enabled to use lower ventilator settings while simultaneously reducing the risk of VILI. Major market participants, including Medtronic, Getinge AB, and XENIOS, are investing capital in research and development, as well as corporate actions, to enhance device safety, reduce the occurrence of thrombosis, and facilitate the advancement of clinical applications beyond the ICU.

The scope of the extracorporeal CO2 removal devices market report encompasses an assessment of the market performance in North America, Europe, the Asia Pacific, South America, Central America, the Middle East, and Africa. Regarding revenue, North America dominated the extracorporeal CO2 removal devices market in 2024.

The extracorporeal CO2 removal devices market in North America is segmented into the US, Canada, and Mexico. The Extracorporeal CO2 Removal market in North America is experiencing rapid growth, partly due to the region's advanced healthcare infrastructure, the rising prevalence of respiratory diseases, and the increasing adoption of cutting-edge medical technologies. In general, such areas, especially the US and Canada, are characterized by outstanding and efficient healthcare systems with significant financial flows in the fields of intensive care and respiratory therapy. Furthermore, investments in healthcare infrastructure and digital health integration are expected to ensure the safe management of patients with respiratory failure, thereby paving the way for a positive outlook for the region. The presence of clinicians adept in their specialties and the development of technology, among other factors, such as supportive policies and, not to forget, the high prevalence of the disease, make North America the leader in the market of ECCO?R devices by far and put it amongst the rapidly emerging markets with the brightest healthcare results improvement prospects in respiratory care solutions.

The US is a major player in the global ECCO?R devices market, serving as the primary driver for this market due to its stable healthcare infrastructure, high prevalence of respiratory disorders, and thriving clinical research environment. In 2022, the ECCO?R market in the US had the largest share. Such supremacy is primarily due to the widespread application of ECCO?R systems in tertiary care hospitals and university medical centers in the country. This, along with incentives that cover the costs and an intense focus on innovating in critical care, has played a significant role in this regard. Companies such as Medtronic, Getinge, and ALung Technologies have been highly effective in advancing ECCO?R systems by focusing on optimizing technical devices and patient recovery, as well as the effectiveness of applied technologies in various clinical cases. Gradually, as more cases of COPD (chronic obstructive pulmonary disease) and ARDS (acute respiratory distress syndrome) are identified, and other relevant lung pathologies emerge, these conditions will increasingly require the use of advanced therapeutic interventions, driving the growth of the extracorporeal CO2 removal devices market in the future.

Medtronic Plc, Fresenius Medical Care AG & Co KGaA, Baxter International Inc, Eurosets SRL, Getinge AB, Medica S.p.A., Aferetica s.r.l., LivaNova Plc, ESTOR S.P.A., and Terumo Corp are among the leading companies profiled in the extracorporeal CO2 removal devices market report.

Based on product, the extracorporeal CO2 removal devices market is bifurcated into extracorporeal CO2 devices and consumables. In terms of application, the extracorporeal CO2 removal devices market is categorized into chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others. In terms of end user, the extracorporeal CO2 removal devices market is categorized into hospitals and clinics, ambulatory surgical centers, and others. The hospitals and clinics segment held the largest share of the extracorporeal CO2 removal devices market in 2024. Based on geography, the market is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com